Drugs / Vero cell rabies vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03700242 | Sep 2018 → Jan 2019 | — | Sanofi Pasteur, a Sanofi Company | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vero cell rabies vaccine | “one 0.5 mL IM dose (Group 4) or two 0.1 mL ID doses (Group 5) of Vero cell rabies vaccine (PVRV) at each visit” PMID 35933278 ↗ Aug 2022 |
| Known as | PVRV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03700242 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular” NCT03700242 ↗ |